HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Skin Care Continues Apace With ‘Rapid’ Products, ‘1 Week’ Claims

This article was originally published in The Rose Sheet

Executive Summary

Regulatory and legal challenges have not held back J&J/Neutrogena’s Rapid Wrinkle Repair business, which has been joined by a Rapid Tone Repair line and Rapid Clear acne treatments. Meanwhile, new Aveeno Absolutely Ageless products similarly provide results in just one week, the company says.

You may also be interested in...



L’Oreal’s Anti-Wrinkle RevitaLift Products Are Unlawfully Marketed Drugs – Class Action Complaint

The proposed class action against L’Oreal in California’s Central District is a reminder that anti-aging skin care can be a target for legal challenges, and the plaintiffs’ bar isn’t tired of bringing them.

FDA Warnings Slow, But Anti-Aging Claims Remain Class Action Targets

The online universe is abuzz with complaints about 2016, with some ready to dub the year “worst ever.” It certainly was a rough one for anti-aging skin-care marketers, and while FDA’s warning letter activity has declined of late, consumer lawsuits continue to file challenging companies’ clock-reversing promises.

J&J Consumer Products Business Steers Toward Acquisitions For Growth

Firm continues to be outspoken about its M&A appetite, recently closing deals for Vogue International and NeoStrata, among others. Neutrogena and Aveeno were top performers for J&J’s Consumer business in the second quarter, the company says.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108463

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel